Brief: Everest Medicines Says Partner Calliditas Therapeutics Receives FDA Priority Review For Full Approval Of Nefecon
21/08/2023 01:36
Aug 20 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES PARTNER CALLIDITAS
THERAPEUTICS
RECEIVES FDA PRIORITY REVIEW FOR FULL APPROVAL OF NEFECON® FOR
THE TREATMENT OF IGA NEPHROPATHY
* PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE IS DEC.
20,
2023.
Source text for Eikon: ID:nPn7KV3v9a
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region